Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-106550
Filing Date
2025-08-11
Accepted
2025-08-11 16:10:29
Documents
76
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atra-20250630.htm   iXBRL 10-Q 3116536
2 EX-10.1 atra-ex10_1.htm EX-10.1 59810
3 EX-31.1 atra-ex31_1.htm EX-31.1 15304
4 EX-31.2 atra-ex31_2.htm EX-31.2 15342
5 EX-32.1 atra-ex32_1.htm EX-32.1 11254
  Complete submission text file 0000950170-25-106550.txt   11343647

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atra-20250630.xsd EX-101.SCH 1384037
79 EXTRACTED XBRL INSTANCE DOCUMENT atra-20250630_htm.xml XML 2148634
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36548 | Film No.: 251202089
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)